Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease (Q67705350)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 1991

Language	Label	Description	Also known as
English	Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease	scientific article published on 01 October 1991

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

total body irradiation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

author name string

A. M. Gianni

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

S. Siena

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

M. Bregni

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

F. Lombardi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

L. Gandola

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

P. Valagussa

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

G. Bonadonna

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1720655

8 November 2022

publication date

1 October 1991

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

full work available at URL

http://annonc.oxfordjournals.org/cgi/content/abstract/2/9/645

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1720655

8 November 2022

https://api.elsevier.com/content/article/PII:S0923753420306657?httpAccept=text/xml

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

https://api.elsevier.com/content/article/PII:S0923753420306657?httpAccept=text/plain

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

http://academic.oup.com/annonc/article-pdf/2/9/645/618681/2-9-645.pdf

Portable Document Format

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

645-653

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

2

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Can MOPP be replaced in the treatment of advanced Hodgkin's disease?

3

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

5

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission

6

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Salvage treatments in Hodgkin's disease

7

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Is there an effective salvage therapy for advanced Hodgkin's disease?

8

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

9

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

10

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

11

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support

12

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

16

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?

17

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

18

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Alternating versus hybrid MOPP-ABVD in Hodgkin’s disease: The Milan experience

19

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma

22

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Recent advances in the chemotherapy of metastatic osteogenic sarcoma

23

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation

25

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study

27

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Hepatic veno-occlusive disease

28

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Early and late complications of bone marrow transplantation.

29

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

30

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease

31

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate

32

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood

33

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

35

1 reference

10.1093/OXFORDJOURNALS.ANNONC.A058043

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058043

8 November 2022

Identifiers

10.1093/OXFORDJOURNALS.ANNONC.A058043

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1720655%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67705350&oldid=1767052420"